CAR-T cell therapy for advanced solid tumors with CD73 or AXL
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy designed to target two proteins, CD73 and AXL, found on cancer cells. It is for people with advanced or metastatic solid tumors (like bile duct, pancreatic, lung, breast, head and neck, or gynecologic cancers) who have not responded to standard treatment or have no standard first-line therapy available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your tumor has tested positive for CD73 or AXL in at least half of the cells.
- You have tried at least one prior line of treatment, or your cancer type has no recommended standard first therapy.
- You have a measurable tumor (by scan) and are willing to provide a fresh or recent tumor sample.
- Your blood counts, kidney function, liver function, and heart function are within acceptable ranges.
- You have not had certain other cancers in the last 5 years, except for some minor types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.